With the latest deal, Aventiv became the fourth clinical research firm to join Centricity.
The company has study sites in Ohio and Arizona and focuses on Phase I-IV pharmaceutical, device and diagnostic clinical trials in various therapeutic regions.
Established in 2007, Aventiv has carried out over 475 clinical trials with more than 55 pharmaceutical sponsors, facilitating Food and Drug Administration (FDA) approval and availability for use of 26 drugs.
Centricity Research CEO Dr Jeff Kingsley said: “I am thrilled to have Aventiv join Centricity Research. They will further strengthen and solidify our reputation of prominence and importance within the industry.”
“Aventiv shares our passion for customer-centric and team-centric thinking and promises to be the perfect addition as we continue to revolutionize research and change lives.”
Through the merger with Aventiv, Centricity now provides contract research organisations (CROs) and sponsors access to 45 clinical trial sites.
Furthermore, Centricity offers more than 1.6 million geographically and ethnically diverse participants and over 150 skilled investigators who carry out trials in over 35 therapeutic areas, including neurology, infectious disease, oncology, dermatology, endocrinology, cardiology and vaccines among others.
Centricity has more than 45 research offices in North America and carries out Phase I-IV clinical trials in more than 35 therapeutic areas.
The IRO was launched in November last year when IACT Health and LMC Manna Research joined forces, followed by merger with True North Clinical Research in December.